文献速递心境障碍精神分裂症与精神病性障碍焦虑、强迫与应激相关障碍

经颅直流电刺激对多种健康结局的疗效与安全性:随机临床试验伞状综述

Effects and safety of transcranial direct current stimulation on multiple health outcomes: an umbrella review of randomized clinical trials.
PubMed 文献 · Mol Psychiatry · 2024-05-30

该伞状综述系统评估了经颅直流电刺激(tDCS)对多种神经精神障碍的疗效与安全性,纳入15项随机对照试验的荟萃分析(含282篇原始文献、22个健康终点)。结果显示tDCS对卒中后抑郁、强迫症、精神分裂症工作记忆、偏头痛、注意缺陷多动障碍等症状有改善作用,但证据确定性从极低到高不等,且报告了治疗诱发的躁狂或轻躁狂病例增加。

要点

  • tDCS对卒中后抑郁量表评分(eSMD 1.61, 95%CI 0.72-2.50)和强迫症症状(0.81, 95%CI 0.44-1.18)有改善,证据确定性分别为中和高。
  • tDCS可改善精神分裂症患者的工作记忆(0.34, 95%CI 0.01-0.67, GRADE高)和洞察力评分(GRADE中)。
  • tDCS报告的治疗诱发躁狂或轻躁狂病例增加(0.88, 95%CI 0.62-1.13, GRADE中),需关注安全性。

核心结论

  • tDCS对卒中、强迫症、纤维肌痛、意识障碍、精神分裂症、偏头痛、注意缺陷多动障碍、抑郁、小脑性共济失调和疼痛等多种神经精神疾病有疗效,但证据确定性从极低到高不等。

研究设计与样本

  • 伞状综述,遵循PROSPERO预注册方案(CRD42023458700),纳入15项随机对照试验的荟萃分析,覆盖282篇原始文献、22个健康终点、22个国家和六大洲。
  • 采用AMSTAR 2评估纳入荟萃分析的方法学质量(高3项、中3项、低9项),采用GRADE评估证据确定性。

主要发现

  • 卒中后抑郁量表评分改善的eSMD为1.61(95%CI 0.72-2.50),GRADE中等;日常生活活动独立性改善为7.04(95%CI 3.41-10.67),GRADE高。
  • 上肢运动恢复eSMD为0.15(95%CI 0.06-0.24),下肢运动恢复为0.10(95%CI 0.03-0.16),GRADE均为高。
  • 强迫症症状改善eSMD为0.81(95%CI 0.44-1.18),GRADE高;精神分裂症工作记忆改善为0.34(95%CI 0.01-0.67),GRADE高。
  • 偏头痛相关疼痛改善eSMD为-1.52(95%CI -2.91至-0.13),GRADE高;注意缺陷多动障碍总体症状严重度降低0.24(95%CI 0.04-0.45),GRADE低。
  • 治疗诱发的躁狂或轻躁狂报告病例增加,eSMD为0.88(95%CI 0.62-1.13),GRADE中等。

关键数值与推荐

  • 卒中后抑郁量表评分eSMD 1.61(95%CI 0.72-2.50),GRADE中等。
  • 强迫症症状eSMD 0.81(95%CI 0.44-1.18),GRADE高。
  • 精神分裂症工作记忆eSMD 0.34(95%CI 0.01-0.67),GRADE高。
  • 偏头痛相关疼痛eSMD -1.52(95%CI -2.91至-0.13),GRADE高。
  • 治疗诱发躁狂或轻躁狂eSMD 0.88(95%CI 0.62-1.13),GRADE中等。

临床怎么用

  • tDCS可作为卒中后运动与日常活动恢复、强迫症、精神分裂症工作记忆及偏头痛相关疼痛的辅助治疗选项,但需结合证据确定性等级个体化决策。
  • 使用tDCS时应监测治疗诱发的躁狂或轻躁狂症状,尤其对心境障碍风险人群。

局限性

  • 纳入的荟萃分析方法学质量不一(AMSTAR 2低质量9项),证据确定性从极低到高不等,部分结局证据确定性低或极低。
  • 需进一步研究理解tDCS的潜在机制并优化其治疗潜力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Transcranial direct current stimulation (tDCS), which delivers a direct current to the brain, emerged as a non-invasive potential therapeutic in treating a range of neurological and neuropsychiatric disorders. However, a comprehensive quantitative evidence synthesis on the effects of tDCS on a broad range of mental illnesses is lacking. Here, we systematically assess the certainty of the effects and safety of tDCS on several health outcomes using an umbrella review of randomized controlled trials (RCTs). The methodological quality of each included original meta-analysis was assessed by the A Measurement Tool for Assessing Systematic Reviews 2 (AMSTAR2), and the certainty of the evidence for each effect was evaluated with Grading of Recommendations, Assessment, Development, and Evaluation (GRADE). We followed an a priori protocol (PROSPERO CRD42023458700). We identified 15 meta-analyses of RCTs (AMSTAR 2; high 3, moderate 3, and low 9) that included 282 original articles, covering 22 unique health endpoints across 22 countries and six continents. From meta-analyses of RCTs supported by very low to high certainty of evidence, it was found that tDCS improved symptoms related to post-stroke, including post-stroke depression scale score (equivalent standardized mean difference [eSMD], 1.61 [95% confidence level, 0.72-2.50]; GRADE=moderate), activities of daily living independence (7.04 [3.41-10.67]; GRADE=high), motor recovery of upper and lower extremity (upper extremity: 0.15 [0.06-0.24], GRADE=high; lower extremity: 0.10 [0.03-0.16], GRADE=high), swallowing performance (GRADE=low), and spasticity (GRADE=moderate). In addition, tDCS had treatment effects on symptoms of several neurological and neuropsychiatric disorders, including obsessive-compulsive disorder (0.81 [0.44-1.18]; GRADE=high), pain in fibromyalgia (GRADE=low), disease of consciousness (GRADE=low), insight score (GRADE=moderate) and working memory (0.34 [0.01-0.67]; GRADE=high) in schizophrenia, migraine-related pain (-1.52 [-2.91 to -0.13]; GRADE=high), attention-deficit/hyperactivity disorder (reduction in overall symptom severity: 0.24 [0.04-0.45], GRADE=low; reduction in inattention: 0.56 [0.02-1.11], GRADE=low; reduction in impulsivity: 0.28 [0.04-0.51], GRADE=low), depression (GRADE=low), cerebellar ataxia (GRADE=low), and pain (GRADE=very low). Importantly, tDCS induced an increased number of reported cases of treatment-emergent mania or hypomania (0.88 [0.62-1.13]; GRADE=moderate). We found varied levels of evidence for the effects of tDCS with multiple neurological and neuropsychiatric conditions, from very low to high certainty of evidence. tDCS was effective for people with stroke, obsessive-compulsive disorder, fibromyalgia, disease of consciousness, schizophrenia, migraine, attention-deficit/hyperactivity disorder, depression, cerebellar ataxia, and pain. Therefore, these findings suggest the benefit of tDCS for several neurological and neuropsychiatric disorders; however, further studies are needed to understand the underlying mechanism and optimize its therapeutic potential.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Kang J, Lee H, Yu S, et al. Effects and safety of transcranial direct current stimulation on multiple health outcomes: an umbrella review of randomized clinical trials. Mol Psychiatry. 2024. PMID: 38816583. doi:10.1038/s41380-024-02624-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。